Is Compass Pathways a Buy?
Psychedelics have been long vilified, and are still illegal. Yet there may be situations where these narcotics are actually helpful to people. Studies have suggested that both MDMA (street name, "ecstasy") and psilocybin ("magic mushrooms") can help people who suffer from post-traumatic stress disorder and serious depression. In both cases the drugs are combined with talk therapy.
Compass Pathways (NASDAQ: CMPS) is focused on using psilocybin in human trials for people who have treatment-resistant depression. How big is this market opportunity? Corinne Cardina, bureau chief of Healthcare and Cannabis at Fool.com, and Motley Fool writer Taylor Carmichael discussed the stock on Fool Live. This segment was recorded on May 14.
Source Fool.com
